Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
13 01 2023
Historique:
received: 03 12 2022
revised: 07 01 2023
accepted: 10 01 2023
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit−risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a study in 2017, we observed that older adults did not seem to receive the same modalities of oral anticoagulants as younger individuals for various reasons. To assess anticoagulation prescribing practices over time, we repeated this cross-sectional study by comparing very old individuals taking DOAC to those taking VKA. Ambulatory individuals aged 80 years and older were included. They were affiliated with the Mutualité Sociale Agricole of Burgundy and were refunded for a medical prescription of oral anticoagulation in March 2021. The demographic characteristics, registered chronic diseases (RCD), number and types of prescribed drugs, and mortality of the DOAC group and the VKA group were compared. A total of 4275 subjects were included in the study: 67.44% (2883) received DOAC and 32.56% (1392) received VKA. The two groups were similar in age. In the DOAC group, there were more women (54.98% vs. 46.98%) (p < 0.001), fewer RCD (91.47% vs. 93.68%) (p = 0.014), and lower rates of venous thromboembolism (2.53% vs. 6.75%) (p < 0.001), severe heart failure (56.50% vs. 68.03%) (p < 0.001), and severe kidney diseases (1.38% vs. 3.59%) (p < 0.001), but there were more subjects with Alzheimer’s disease (7.49% vs. 4.31%) (p = 0.001). Individuals in the DOAC group had fewer prescriptions of furosemide (48.53% vs. 55.75%) (p < 0.001) and fibrates (2.32% vs. 3.88%) (p = 0.044). They also had more prescriptions of proton pump inhibitors (43.95% vs. 39.44%) (p = 0.006) and antirheumatics (1.60% vs. 0.65%) (p = 0.009) than those in the VKA group. There was no difference in mortality. This study revealed that prescribing practices for DOAC have changed over time.

Identifiants

pubmed: 36674204
pii: ijerph20021448
doi: 10.3390/ijerph20021448
pmc: PMC9859400
pii:
doi:

Substances chimiques

Anticoagulants 0
Fibrinolytic Agents 0
Vitamin K 12001-79-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Environ Res Public Health. 2021 Apr 22;18(9):
pubmed: 33922331
JAMA Cardiol. 2020 Jun 1;5(6):685-692
pubmed: 32320043
Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):405-414
pubmed: 33010157
Ann Neurol. 2022 Jan;91(1):78-88
pubmed: 34747514
J Thromb Haemost. 2013 Mar;11(3):402-11
pubmed: 23297815
JAMA Intern Med. 2022 Dec 1;182(12):1260-1266
pubmed: 36315125
J Am Heart Assoc. 2018 Jan 26;7(3):
pubmed: 29374049
J Thromb Thrombolysis. 2016 Jan;41(1):206-32
pubmed: 26780747
Cochrane Database Syst Rev. 2014 Mar 27;(3):CD009893
pubmed: 24677203
Chest. 2012 Feb;141(2 Suppl):e44S-e88S
pubmed: 22315269
Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A1-A10
pubmed: 35185404
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Ann Cardiol Angeiol (Paris). 2017 Sep;66(4):197-203
pubmed: 28506577
JHEP Rep. 2019 Jul 16;1(3):227-239
pubmed: 32039373
Rev Med Interne. 2006 Dec;27(12):979-82
pubmed: 17070618
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
Br J Haematol. 2018 Oct;183(2):170-184
pubmed: 30183070
Sci Rep. 2017 Jun 13;7(1):3347
pubmed: 28611403
Semin Thromb Hemost. 2015 Jul;41(5):447-54
pubmed: 26049068
J Am Heart Assoc. 2019 Mar 5;8(5):e011112
pubmed: 30834802
Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):202-213
pubmed: 33822030
Thromb Haemost. 2020 Jul;120(7):1066-1074
pubmed: 32455439
Adv Ther. 2020 May;37(5):1910-1932
pubmed: 32285340
Thromb Haemost. 2012 Jun;107(6):1100-6
pubmed: 22535516
Lancet. 1993 Nov 20;342(8882):1255-62
pubmed: 7901582
Circulation. 2021 Feb 2;143(5):e72-e227
pubmed: 33332150
Eur Heart J Suppl. 2019 Dec;21(Suppl L):L12-L16
pubmed: 31885506
Europace. 2021 Oct 9;23(10):1612-1676
pubmed: 33895845
Geriatr Gerontol Int. 2012 Jan;12(1):16-22
pubmed: 22188494
J Thromb Haemost. 2014 Oct;12(10):1580-90
pubmed: 25302663
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Ann Intern Med. 2021 Sep;174(9):1214-1223
pubmed: 34280330
Stroke. 1996 Oct;27(10):1760-4
pubmed: 8841325
Int J Nephrol Renovasc Dis. 2017 Jun 12;10:135-143
pubmed: 28652799
Eur Heart J. 2021 Oct 21;42(40):4194
pubmed: 34520521
Ann Pharmacother. 2019 Oct;53(10):1042-1049
pubmed: 30947523
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Geriatr Gerontol Int. 2017 Jun;17(6):925-930
pubmed: 27255430
Ann Rheum Dis. 2019 Oct;78(10):1296-1304
pubmed: 31092409
Geriatr Psychol Neuropsychiatr Vieil. 2019 Dec 1;17(4):341-354
pubmed: 32912842
Can J Gastroenterol Hepatol. 2019 Jun 18;2019:9851307
pubmed: 31316948
J Thromb Haemost. 2014;12(3):320-8
pubmed: 24330006
J Thromb Haemost. 2020 Jun;18(6):1390-1397
pubmed: 32170987
Neural Regen Res. 2021 Aug;16(8):1556-1557
pubmed: 33433480
Rev Med Interne. 2020 Sep;41(9):598-606
pubmed: 32674901
J Am Heart Assoc. 2020 Jul 7;9(13):e017559
pubmed: 32538234
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724

Auteurs

Chana Azzoug (C)

"Pôle Personnes Âgées", Hospital of Champmaillot, University Hospital, 21079 Dijon, France.

Gilles Nuémi (G)

Medical Information Department, University Hospital, 21079 Dijon, France.

Didier Menu (D)

"Mutualité Sociale Agricole" of Burgundy Franche Comté, 21000 Dijon, France.

Emmanuel De Maistre (E)

Haemostasis Unit, University Hospital, 21079 Dijon, France.

Mathieu Boulin (M)

Pharmacy Department, University Hospital, 21079 Dijon, France.

Alain Putot (A)

Department of Internal Medicine and Infectious Diseases, Pays du Mont Blanc Hospital, 74700 Sallanches, France.
Physiopathologie et Épidémiologie Cérébro-Cardiovasculaires (PEC2), EA 7460, University of Burgundy, 21000 Dijon, France.

Patrick Manckoundia (P)

"Pôle Personnes Âgées", Hospital of Champmaillot, University Hospital, 21079 Dijon, France.
INSERM U-1093, Cognition, Action and Sensorimotor Plasticity, University of Burgundy, 21000 Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH